scorecard
  1. Home
  2. Science
  3. Health
  4. news
  5. 5 key challenges facing 23andMe ahead of its public debut

5 key challenges facing 23andMe ahead of its public debut

Lydia Ramsey Pflanzer   

5 key challenges facing 23andMe ahead of its public debut
Science2 min read

Hello,

Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:

If you're new to this newsletter, sign up here. Comments or tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Now, let's get to it...


Some breaking news for you this morning - Pfizer and BioNTech's COVID-19 vaccine was highly effective at preventing infections in kids ages 12 to 15, the company said Wednesday morning. That's according to results from a trial of more than 2,000 12- to 15-year-olds.

Find out more here>>


We just got the best look yet at the consumer genetics market ahead of 23andMe's public debut. Here are the 5 biggest obstacles the $3.6 billion company will have to overcome.

Get the full analysis here>>


The WHO's leader said its investigation into whether the coronavirus leaked from a Wuhan lab was not 'extensive enough'

Find out more here>>



A top Walmart healthcare exec is leaving the retail giant

Read the full memo sent to staff here>>


More stories we're reading:


- Lydia

READ MORE ARTICLES ON


Advertisement

Advertisement